These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Medulloblastoma with transitional features between Group 3 and Group 4 is associated with good prognosis. Łastowska M; Trubicka J; Niemira M; Paczkowska-Abdulsalam M; Karkucińska-Więckowska A; Kaleta M; Drogosiewicz M; Perek-Polnik M; Krętowski A; Cukrowska B; Grajkowska W; Dembowska-Bagińska B; Matyja E J Neurooncol; 2018 Jun; 138(2):231-240. PubMed ID: 29427151 [TBL] [Abstract][Full Text] [Related]
5. Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study. Schwalbe EC; Lindsey JC; Nakjang S; Crosier S; Smith AJ; Hicks D; Rafiee G; Hill RM; Iliasova A; Stone T; Pizer B; Michalski A; Joshi A; Wharton SB; Jacques TS; Bailey S; Williamson D; Clifford SC Lancet Oncol; 2017 Jul; 18(7):958-971. PubMed ID: 28545823 [TBL] [Abstract][Full Text] [Related]
6. Molecular Subgrouping of Medulloblastoma: Impact Upon Research and Clinical Practice. Gupta T; Shirsat N; Jalali R Curr Pediatr Rev; 2015; 11(2):106-19. PubMed ID: 26133181 [TBL] [Abstract][Full Text] [Related]
7. Personalized diagnosis of medulloblastoma subtypes across patients and model systems. Gendoo DM; Smirnov P; Lupien M; Haibe-Kains B Genomics; 2015 Aug; 106(2):96-106. PubMed ID: 25979459 [TBL] [Abstract][Full Text] [Related]
9. Classification of childhood medulloblastoma into WHO-defined multiple subtypes based on textural analysis. Das D; Mahanta LB; Ahmed S; Baishya BK J Microsc; 2020 Jul; 279(1):26-38. PubMed ID: 32271463 [TBL] [Abstract][Full Text] [Related]
10. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial. Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813 [TBL] [Abstract][Full Text] [Related]
11. A Novel Method for Rapid Molecular Subgrouping of Medulloblastoma. Gómez S; Garrido-Garcia A; Garcia-Gerique L; Lemos I; Suñol M; de Torres C; Kulis M; Pérez-Jaume S; Carcaboso ÁM; Luu B; Kieran MW; Jabado N; Kozlenkov A; Dracheva S; Ramaswamy V; Hovestadt V; Johann P; Jones DTW; Pfister SM; Morales La Madrid A; Cruz O; Taylor MD; Martin-Subero JI; Mora J; Lavarino C Clin Cancer Res; 2018 Mar; 24(6):1355-1363. PubMed ID: 29351917 [No Abstract] [Full Text] [Related]
12. DNA-methylation profiling discloses significant advantages over NanoString method for molecular classification of medulloblastoma. Korshunov A; Chavez L; Northcott PA; Sharma T; Ryzhova M; Jones DTW; von Deimling A; Pfister SM; Kool M Acta Neuropathol; 2017 Dec; 134(6):965-967. PubMed ID: 29027579 [No Abstract] [Full Text] [Related]
13. Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. Northcott PA; Shih DJ; Remke M; Cho YJ; Kool M; Hawkins C; Eberhart CG; Dubuc A; Guettouche T; Cardentey Y; Bouffet E; Pomeroy SL; Marra M; Malkin D; Rutka JT; Korshunov A; Pfister S; Taylor MD Acta Neuropathol; 2012 Apr; 123(4):615-26. PubMed ID: 22057785 [TBL] [Abstract][Full Text] [Related]
14. Clinical and pre-clinical utility of genomics in medulloblastoma. Nör C; Ramaswamy V Expert Rev Neurother; 2018 Aug; 18(8):633-647. PubMed ID: 30032687 [TBL] [Abstract][Full Text] [Related]
15. A five-gene hedgehog signature developed as a patient preselection tool for hedgehog inhibitor therapy in medulloblastoma. Shou Y; Robinson DM; Amakye DD; Rose KL; Cho YJ; Ligon KL; Sharp T; Haider AS; Bandaru R; Ando Y; Geoerger B; Doz F; Ashley DM; Hargrave DR; Casanova M; Tawbi HA; Rodon J; Thomas AL; Mita AC; MacDonald TJ; Kieran MW Clin Cancer Res; 2015 Feb; 21(3):585-93. PubMed ID: 25473003 [TBL] [Abstract][Full Text] [Related]
16. p53 Function Is Compromised by Inhibitor 2 of Phosphatase 2A in Sonic Hedgehog Medulloblastoma. Wei Y; Maximov V; Morrissy SA; Taylor MD; Pallas DC; Kenney AM Mol Cancer Res; 2019 Jan; 17(1):186-198. PubMed ID: 30224541 [TBL] [Abstract][Full Text] [Related]
17. Implications of tumor location on subtypes of medulloblastoma. Teo WY; Shen J; Su JM; Yu A; Wang J; Chow WY; Li X; Jones J; Dauser R; Whitehead W; Adesina AM; Chintagumpala M; Man TK; Lau CC Pediatr Blood Cancer; 2013 Sep; 60(9):1408-10. PubMed ID: 23512859 [TBL] [Abstract][Full Text] [Related]
18. Identification of cell surface targets through meta-analysis of microarray data. Haeberle H; Dudley JT; Liu JT; Butte AJ; Contag CH Neoplasia; 2012 Jul; 14(7):666-9. PubMed ID: 22904683 [TBL] [Abstract][Full Text] [Related]
19. Molecular Classification of Medulloblastoma. Kijima N; Kanemura Y Neurol Med Chir (Tokyo); 2016 Nov; 56(11):687-697. PubMed ID: 27238212 [TBL] [Abstract][Full Text] [Related]
20. Molecular subgroups of medulloblastoma: the current consensus. Taylor MD; Northcott PA; Korshunov A; Remke M; Cho YJ; Clifford SC; Eberhart CG; Parsons DW; Rutkowski S; Gajjar A; Ellison DW; Lichter P; Gilbertson RJ; Pomeroy SL; Kool M; Pfister SM Acta Neuropathol; 2012 Apr; 123(4):465-72. PubMed ID: 22134537 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]